Humira vs SKYRIZI
Side-by-side comparison of Humira and SKYRIZI — mechanism, indications, safety, trials, sponsor, and pricing.
At a glance
| Humira | SKYRIZI |
|---|
| Generic name | Humira | SKYRIZI |
|---|
| Sponsor | Sohag University | Chong Kun Dang Pharmaceutical |
|---|
| Drug class | — | IL-23 inhibitor monoclonal antibody |
|---|
| Molecular target | Tumor necrosis factor | IL-23 (p19 subunit) |
|---|
| Modality | Small molecule | Biologic |
|---|
| Phase | FDA-approved | FDA-approved |
|---|
| Therapeutic area | Oncology | Immunology/Dermatology |
|---|
Mechanism of action
| Humira | — |
|---|
| SKYRIZI | SKYRIZI (risankizumab) is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23. |
|---|
Approved indications
Humira
- Ankylosing spondylitis
- Axial spondyloarthritis
- Behcet's disease
- Crohn's disease
- Hidradenitis suppurativa
- Juvenile idiopathic arthritis
- Non-infectious anterior uveitis
- Non-infectious intermediate, posterior and panuveitis
SKYRIZI
- Moderate to severe plaque psoriasis
- Crohn's disease
- Ulcerative colitis
Common side effects
Humira
- Injection site reactions
- Infections (upper respiratory, sinusitis)
- Headache
- Rash
SKYRIZI
- Upper respiratory tract infection
- Injection site reactions
- Headache
- Fatigue
Further reading